1. Introduction {#sec1-marinedrugs-17-00593}
===============

Microbially produced natural products (NPs) are an important reservoir of therapeutic and agricultural agents \[[@B1-marinedrugs-17-00593]\]. In the previous years, quantities of new bioactive NPs were isolated from marine-derived *Streptomyces* strains, suggesting marine-derived *Streptomyces* as a predominant source of new NPs \[[@B2-marinedrugs-17-00593]\]. In recent years, whole-genome sequencing programs have made it clear that microorganisms have greater biosynthetic potential but are mostly underexplored by virtue that most biosynthetic gene clusters (BGCs) in a single microbial genome are normally silent. Activation of these silent BGCs contributes to new NPs discoveries. Zhang and co-workers activated a cryptic polycyclic tetramate macrolactam (PTM) BGC in *Streptomyces pactum* SCSIO 02999 by promoter engineering and heterologous expression \[[@B3-marinedrugs-17-00593]\], and also promoted the expression of a silent PKS/NRPS hybrid BGC in the same *Streptomyces* strain by the alteration of several regulatory genes \[[@B4-marinedrugs-17-00593]\]. The production of nocardamine \[[@B5-marinedrugs-17-00593]\] and atratumycin \[[@B6-marinedrugs-17-00593]\] in *Streptomyces atratus* SCSIO ZH16 was turned on via metabolic engineering. These genome-based studies exemplify the benefits of genome mining and metabolic engineering used for activating cryptic BGCs and discovering new bioactive NPs.

Lobophorins ([Supporting Information (SI), Figure S1](#app1-marinedrugs-17-00593){ref-type="app"}) belonging to a large class of spirotetronate antibiotics structurally feature a tetronate moiety *spiro*-linked with a cyclohexene ring, which is called pentacyclic aglycon or kijanolide \[[@B7-marinedrugs-17-00593],[@B8-marinedrugs-17-00593],[@B9-marinedrugs-17-00593],[@B10-marinedrugs-17-00593],[@B11-marinedrugs-17-00593],[@B12-marinedrugs-17-00593],[@B13-marinedrugs-17-00593],[@B14-marinedrugs-17-00593],[@B15-marinedrugs-17-00593],[@B16-marinedrugs-17-00593],[@B17-marinedrugs-17-00593]\]. Almost all of this class of compounds has a broad spectrum of antibacterial activities, as well as antitumor activity. Efforts to produce more spirotetronate antibiotics for drug discovery have thrived. Owing to the structural complexity of this family member, biosynthesis seems to be an effective way to afford the production of spirotetronate antibiotics, providing access to new analogues by pathway engineering and combinatorial biosynthetic approaches. In this paper, we report (i) the complete genome sequence of a deep-sea-derived *Streptomyces olivaceus* SCSIO T05, a talented strain capable of producing an array of putative NPs; (ii) activation of a cryptic lobophorin BGC (*lbp*) by mutagenetic methods and isolation of one known spirotetronate antibiotic lobophorin CR4 (**1**); and (iii) identification of the *lbp* BGC housed in *S. olivaceus* SCSIO T05 by gene-disruption experiment and bioinformatics analysis.

2. Results and Discussion {#sec2-marinedrugs-17-00593}
=========================

2.1. Genome Sequencing and Annotation of Streptomyces olivaceus SCSIO T05 {#sec2dot1-marinedrugs-17-00593}
-------------------------------------------------------------------------

Whole genome sequence is important when analyzing the potential production of secondary metabolites \[[@B5-marinedrugs-17-00593],[@B18-marinedrugs-17-00593]\]. *S. olivaceus* SCSIO T05, a marine-derived strain, was previously reported to be isolated from the Indian Ocean deep-sea-derived sediment \[[@B19-marinedrugs-17-00593]\]. Its draft genome sequence was first gained by Illumina sequencing technology, but with several gap regions. In order to estimate the biosynthetic potential of *S. olivaceus* SCSIO T05, the complete genome was re-sequenced and acquired by the single-molecule real-time (SMRT) sequencing technology (PacBio). A total of 67156 filtered reads with high-quality data of 432570025 bp were generated, and then they were assembled into a linear contig by the hierarchical genome assembly process (HGAP) \[[@B20-marinedrugs-17-00593]\]. The complete genome revealed that 8458055 base pairs constitute a linear chromosome without a plasmid, with 72.51% of GC content ([Figure 1](#marinedrugs-17-00593-f001){ref-type="fig"} and [Table 1](#marinedrugs-17-00593-t001){ref-type="table"}). Totally, 7700 protein-coding genes were predicted, along with 18 rRNA and 65 tRNA. The genome sequence of *S. olivaceus* SCSIO T05 was deposited in GenBank (CP043317).

AntiSMASH analysis by using antiSMASH 5.0 \[[@B21-marinedrugs-17-00593]\] suggested 37 BGCs within the *S. olivaceus* SCSIO T05 genome ([Figure 1](#marinedrugs-17-00593-f001){ref-type="fig"} and [Table 2](#marinedrugs-17-00593-t002){ref-type="table"}). The 37 BGCs totally occupy 1.59 Mb, 18.76% of the complete genome. Most of the BGCs distribute in the two subtelomeric regions of the genome of some *Streptomyces* strains \[[@B18-marinedrugs-17-00593]\] and so do the BGCs in *S. olivaceus* SCSIO T05 genome. It is predicted that several BGCs are responsible for the production of polyketide- and nonribosome-peptide-derived secondary metabolites, including four PKS (Type I, Type II and Type III) and six NRPS, and six hybrid BGCs possess genes encoding more than one type of scaffold-synthesizing enzyme. Twenty-one BGCs are predicted to produce terpene, bacteriocin, lanthipeptide, or other categories. This analysis indicates that *S. olivaceus* SCSIO T05 is capable of producing an array of secondary metabolites, serving as a target strain for further metabolic engineering and genome mining.

2.2. Activation of a Cryptic Lobophorin BGC in the Genetically Engineered Mutant {#sec2dot2-marinedrugs-17-00593}
--------------------------------------------------------------------------------

In actuality, only a minority of potential chemicals are produced under standard laboratory culture conditions. Furthermore, the corresponding products are likely to be overlooked for multiple reasons, including low production rates, a large metabolic background, or improper culture conditions \[[@B22-marinedrugs-17-00593]\]. Fermented using modified-RA medium, the secondary metabolites produced by *S. olivaceus* SCSIO T05 were subsequently profiled using HPLC-DAD-UV. Multiple peaks were detected in the fermentation extract ([Figure 2](#marinedrugs-17-00593-f002){ref-type="fig"}, trace i). We previously reported that five known NPs, rishirilides B (**2**) and C (**3**), lupinacidin A (**4**), galvaquinone B (**5**), and xiamycin A (**6**), were produced as major secondary metabolites from the wild-type strain \[[@B19-marinedrugs-17-00593],[@B23-marinedrugs-17-00593]\]. In addition, an orphan dibenzoxazepinone biosynthetic pathway was mutagenically activated, leading to the production of new mycemycins \[[@B24-marinedrugs-17-00593]\], suggesting that *S. olivaceus* SCSIO T05 has a great potential for producing new NPs.

For exploring other secondary metabolites from the strain, *S. olivaceus* SCSIO T05/Δ*rsdK*~2~ (*S. olivaceus* SCSIO T05R) was constructed to abolish the production of the anthracenes \[[@B19-marinedrugs-17-00593]\]. The production of the second major secondary metabolites xiamycins was accumulated, along with a new peak around 26 min, distinct from the UV absorption characteristics of xiamycins ([Figure 2](#marinedrugs-17-00593-f002){ref-type="fig"}, trace ii). For further background elimination of xiamycins, a "double-deletion" mutant *S. olivaceus* SCSIO T05/Δ*rsdK*~2~/Δ*xmcP* (*S. olivaceus* SCSIO T05RX) was constructed \[[@B23-marinedrugs-17-00593]\] in which the new peak (**1**) appeared to be the major product ([Figure 2](#marinedrugs-17-00593-f002){ref-type="fig"}, trace iii). Accordingly, the *S. olivaceus* SCSIO T05RX mutant was fermented at a large scale, enabling the isolation and structure elucidation of this newly generated compound. It was identified as a known compound designated as lobophorin CR4 ([Figure 3](#marinedrugs-17-00593-f003){ref-type="fig"}), by comparing HRESIMS, ^1^H, and ^13^C NMR data ([SI, Figures S2--S4](#app1-marinedrugs-17-00593){ref-type="app"}) to the reported data of an intermediate isolated from the *Streptomyces* sp. SCSIO 01127/Δ*lobG1* mutant \[[@B11-marinedrugs-17-00593]\]. It is reported that shifting metabolic flux of a wild-type strain by blocking the predominant product pathways may afford new secondary metabolites \[[@B5-marinedrugs-17-00593]\]. During our efforts to acquire new secondary metabolites by shifting the metabolic flux of marine actinomycetes \[[@B5-marinedrugs-17-00593],[@B23-marinedrugs-17-00593],[@B24-marinedrugs-17-00593]\], the production of nocardamine, olimycins, and mycemycins was turned on at the expense of major products by using gene knock-out methods. Similarly, the "double-deletion" mutant (*S. olivaceus* SCSIO T05RX) was constructed to abolish the production of two major secondary metabolites, anthracenes and xiamycins, from the wild-type strain \[[@B19-marinedrugs-17-00593],[@B23-marinedrugs-17-00593]\]. With the engineered shifting of *S. olivaceus* metabolic flux, the newly produced lobophorin CR4 was activated.

2.3. Identification of a Putative Lobophorin (lbp) BGC via Genome Mining {#sec2dot3-marinedrugs-17-00593}
------------------------------------------------------------------------

The antiSMASH analysis of the complete genome of *S. olivaceus* SCSIO T05 revealed a 99.1 kb type I PKS BGC named as lobophorin BGC (*lbp*), showing highly similar traits to the reported *lob* BGCs from *Streptomyces* sp. FXJ7.023 \[[@B16-marinedrugs-17-00593]\] and *Streptomyces* sp. SCSIO 01127 \[[@B11-marinedrugs-17-00593]\]. The complete *lbp* contains 38 open reading frames (ORFs). The genetic organization of *lbp* is shown in [Figure 4](#marinedrugs-17-00593-f004){ref-type="fig"}A, with genes color-coded on the basis of their proposed functions summarized in [Table 3](#marinedrugs-17-00593-t003){ref-type="table"}. The nucleotide sequences were deposited in GenBank (MN396889). The *lbp* BGC contains six inconsecutive genes *lbpA1*--*A6*, similar to *lobA1*--*A5* in *lob* from *S.* sp. SCSIO 01127. Differently, the LobA4 homologue is separated into two polyketide synthases (PKSs), LbpA4 and LbpA5, in *lbp*. The high similarity between the PKS modules in *lbp* and in *lob* enables us to propose that the assembly of the linear polyketide chain catalyzed by LbpA1--A6 utilizes six malonyl CoAs, six methylmalonyl-CoAs, and a 3-carbon glycerol unit ([Figure 5](#marinedrugs-17-00593-f005){ref-type="fig"}) \[[@B11-marinedrugs-17-00593]\]. The *lbp* harbors four putative regulator genes (*lbpR1--R4*) ([Figure 4](#marinedrugs-17-00593-f004){ref-type="fig"} and [Table 3](#marinedrugs-17-00593-t003){ref-type="table"}) that are highly similar to *lobR1*, *lobR3*, *lobR4*, and *lobR5* in *lob*, respectively. These four regulators are assumed to be involved in the regulation network of lobophorin CR4 biosynthesis, which seems to be less complex than *lob* but more complex than *kij* \[[@B7-marinedrugs-17-00593]\] and *tca* \[[@B8-marinedrugs-17-00593]\]. In contrast, five regulator genes *lobR1--R5* are identified in *lob*; three regulator genes, *kijA8*, *kijC5*, and *kijD12,* are included in *kij*; *tcaR1* and *tcaR2* both encode regulators in *tca*. There is only one gene, *lbpU2* in *lbp*, with no apparent homologue in *lob* ([Figure 4](#marinedrugs-17-00593-f004){ref-type="fig"} and [Table 3](#marinedrugs-17-00593-t003){ref-type="table"}). The other genes included in *lbp* are putatively associated with the biosynthesis of kijanose and [l]{.smallcaps}-digitoxose units by virtue of high similarities to corresponding counterparts in *lob* ([Figure 4](#marinedrugs-17-00593-f004){ref-type="fig"} and [Table 3](#marinedrugs-17-00593-t003){ref-type="table"}).

To demonstrate the validity of the putative *lbp* BGC, *lbpC4* coding for ketosynthase-III-like protein, which incorporates a 3-carbon glycerol unit into the biosynthetic precursor LOB aglycon \[[@B11-marinedrugs-17-00593]\], was disrupted by using PCR-targeting methods. As expected, the production of lobophorin CR4 was completely blocked in *S. olivaceus* SCSIO T05/Δ*rsdK*~2~/Δ*xmcP*/Δ*lbpC4* (*S. olivaceus* SCSIO T05RXL) ([Figure 2](#marinedrugs-17-00593-f002){ref-type="fig"}, trace iv), demonstrating that the *lbp* BGC is indeed responsible for lobophorin biosynthesis. With high similarity to the *lob* BGC, the *lbp* BGC accounts for lobophorin CR4 without the attachment of kijanose to C17-OH, rather than lobophorins A and B in *lob*. Based on bioinformatics analysis, a series of enzymes are proposed to be involved in kijanose biosynthesis ([Figure 5](#marinedrugs-17-00593-f005){ref-type="fig"}) \[[@B7-marinedrugs-17-00593]\]. Among them, the amino acid sequence of the putative FAD-dependent oxidoreductase LbpP2 is far shorter than its homologues LobP2 \[[@B11-marinedrugs-17-00593]\] and KijB3 \[[@B7-marinedrugs-17-00593]\]. KijB3 is proposed to oxidize the methyl group to a carboxylate group, essential for the generation of the kijanose moiety \[[@B7-marinedrugs-17-00593]\]. Multiple protein sequence alignments of LbpP2, LobP2, and KijB3 revealed that the conserved FAD binding domain is missing in LbpP2 ([Figure S5](#app1-marinedrugs-17-00593){ref-type="app"}). Thus, we speculate that LbpP2 is nonfunctional, failing to catalyze the carboxylation and hinder the generation of kijanose.

Given the high similarity of LbpG3 and LobG3, we envision that LbpG3 has a similar function as LobG3, a glycosyltransferase from *S.* sp. SCSIO 01127, tandemly attaching the first two [l]{.smallcaps}-digitoxose at C-9 in lobophorins \[[@B11-marinedrugs-17-00593]\]. LbpG2 has 99% similarity to LobG2, another glycosyltransferase from the same strain, which was established to transfer the terminal [l]{.smallcaps}-digitoxose \[[@B11-marinedrugs-17-00593]\]. Both LbpG2 and LbpG3 are likely to be involved in the transfers of three sugar units, sugars A, B, and C, in lobophorin CR4 ([Figure 5](#marinedrugs-17-00593-f005){ref-type="fig"}), consistent with the metabolite profile of Δ*lobG1* in *S.* sp. SCSIO 01127 \[[@B11-marinedrugs-17-00593]\].

3. Experimental Section {#sec3-marinedrugs-17-00593}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-17-00593}
------------------------------------

The plasmids and bacteria used are listed in [Table S1](#app1-marinedrugs-17-00593){ref-type="app"}. *Streptomyces olivaceus* SCSIO T05 and its mutants were incubated on modified ISP-4 medium \[[@B25-marinedrugs-17-00593]\] with 3% sea salt and fermented in modified RA medium \[[@B19-marinedrugs-17-00593]\]. All cultures for *Streptomyces* were incubated at 28 °C. Luria-Bertani (LB) medium was used for *E. coli*, with appropriate antibiotics added at a final concentration of 100 µg/mL of ampicillin (Amp), 50 µg/mL of kanamycin (Kan), 50 µg/mL of apramycin (Apr), 25 µg/mL of chloroamphenicol (Cml), and 50 µg/mL of trimethoprim (TMP).

A 1260 infinity system (Agilent, Santa Clara, CA, USA), which uses a Phenomenex Prodigy ODS (2) column (150 × 4.6 mm, 5 μm, USA), was used for HPLC-based analyses. Silica gel with the size of 100--200 mesh (Jiangpeng Silica gel development, Inc., Shandong, China) was used for column chromatography (CC). A Primaide 1110 solvent delivery module, which is equipped with a 1430 photodiode array detector (Hitachi, Tokyo, Japan) and uses a YMC-Pack ODS-A column (250 mm × 10 mm, 5 μm), was used for semi-preparative HPLC. A MaXis Q-TOF mass spectrometer (Bruker, Billerica, MA, USA) was used to acquire high-resolution mass spectral data. An MCP-500 polarimeter (Anton Paar, Graz, Austria) was used to record optical rotations. A Bruker Avance 500 was used to record NMR spectra. Carbon signals and the residual proton signals of DMSO-*d*~6~ were used for calibration (*δ*~C~ 39.52 and *δ*~H~ 2.50).

3.2. Genome Sequencing and Bioinformatic Analysis {#sec3dot2-marinedrugs-17-00593}
-------------------------------------------------

Whole genome scanning and annotation of *S. olivaceus* SCSIO T05 were acquired by the single-molecule real-time (SMRT) sequencing technology (PacBio) at Shanghai Majorbio Bio-Pharm Technology Co., Ltd (Shanghai, China). AntiSMASH (AntiSMASH 5.0, available at <http://antismash.secondarymetabolites.org/>) was used to analyze and assess the potential BGCs. FramePlot (FramePlot 4.0 beta, available at <http://nocardia.nih.go.jp/fp4/>) was used to analyze ORFs whose functions were predicted based on an online BLAST program (<http://blast.ncbi.nlm.nih.gov/>).

3.3. Construction of a "Triple-Deletion" Mutant Strain {#sec3dot3-marinedrugs-17-00593}
------------------------------------------------------

Gene *lbpC4* from the *lbp* BGC was inactivated by the REDIRECT protocol \[[@B26-marinedrugs-17-00593]\]. All primers used in this study are listed in [Table S2](#app1-marinedrugs-17-00593){ref-type="app"}. *LbpC4* was replaced by the apramycin resistance gene *oriT*/*aac(3)IV* fragment in the target cosmids 01-07D or 21-02E. The target mutant clones, *S. olivaceus* SCSIO T05RXL, were accomplished as previously described \[[@B19-marinedrugs-17-00593],[@B23-marinedrugs-17-00593],[@B24-marinedrugs-17-00593]\].

3.4. Fermentation and HPLC-based Analyses of S. olivaceus SCSIO T05 and Its Mutants {#sec3dot4-marinedrugs-17-00593}
-----------------------------------------------------------------------------------

The *Streptomyces* used in this study were incubated in modified ISP-4 medium plates for 2--3 d. For fermentation, a portion of mycelium and spores was seeded into 50 mL of modified RA medium in a 250 mL flask and then shaken at 200 rpm and 28 °C for 8 d. The cultures were extracted with an equal volume of butanone. Organic phases were then dissolved in CH~3~OH (1 mL) after having been evaporated to dryness, and 40 µL of each relevant sample was injected for HPLC-based analysis. The UV detection was at 254 nm. Solvent A is composed of 85% ddH~2~O and 15% CH~3~CN, supplemented with 0.1% HOAc. Solvent B is composed of 85% CH~3~CN and 15% ddH~2~O, supplemented with 0.1% HOAc. Samples were analyzed via the following method: a linear gradient from 0% to 80% solvent B in 20 min, and then, from 80% to 100% solvent B for 1.5 min, finally eluted with 100% solvent B in 6.5 min. The flow rate was 1.0 mL/min.

3.5. Production, Isolation, and Structure Elucidation of Lobophorin CR4 {#sec3dot5-marinedrugs-17-00593}
-----------------------------------------------------------------------

The mycelium of *S. olivaceus* SCSIO T05RX were inoculated into 50 mL of modified-RA medium and then shaken at 200 rpm and 28 °C for 2 d, to gain the seed cultures. After that, the seed cultures were transferred into 150 mL of modified-RA medium and shaken at 200 rpm and 28 °C for 8 d. After the large-scale fermentation was accomplished, a total of 12 L of the growth culture was centrifuged at 4000 g for 10 min to separate the supernatant and mycelium and further extracted by butanone and acetone, respectively. The two organic phases were concentrated (via solvent removal under vacuum), and the residues were combined. The combined sample was subjected to normal phase silica gel CC eluted with CHCl~3~-CH~3~OH (100:0, 98:2, 96:4, 94:6, 92:8, 90:10, 85:15, 80:20, 70:30, 50:50, v/v, each solvent combination in 250 mL volume) to give ten fractions (AFr.1--AFr.10). Fractions A1-A3 were purified to afford the accumulation of compound **1** (98 mg), by preparative HPLC, eluting with 90% solvent B (A: H~2~O; B: CH~3~CN) over the course of 30 min. The flowrate was 2.5 mL/min and the UV detection was at 254 nm. The purified compound was subjected to MS, ^1^H, and ^13^C NMR spectra measurements and elucidated as a known intermediate **3** during lobophorins A and B biosynthesis \[[@B11-marinedrugs-17-00593]\], and we named it lobophorin CR4 (**1**).

4. Conclusions {#sec4-marinedrugs-17-00593}
==============

In this study, we acquired the complete genome sequence of *S. olivaceus* SCSIO T05. The biosynthetically talented strain harbors 37 putative BGCs analyzed by antiSMASH. To explore the biosynthetic potential of this strain, metabolic engineering and genome mining were performed. The major anthracenes and indolosesquiterpenes biosynthetic pathways were blocked, and an orphan spirotetronate antibiotics BGC (*lbp*) was activated in *S. olivaceus* SCSIO T05, leading to the isolation and identification of one known compound, lobophorin CR4. We have identified the *lbp* BGC accounting for lobophorin biosynthesis by gene-disruption experiments and bioinformatics analysis. The production of lobophorin CR4 without the attachment of [d]{.smallcaps}-kijanose to C17-OH was on account that the nonfunctional FAD-dependent oxidoreductase LbpP2 failed to generate [d]{.smallcaps}-kijanose. This work highlights that metabolic engineering and genome mining are the effective ways to turn on putative orphan or silent BGCs to acquire new NPs for drugs discovery.
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![The complete genome of *S. olivaceus* SCSIO T05. The three circles (inner to outer) represent forward GC content, GC skew, and the distribution of putative biosynthetic gene clusters (BGCs) (represented by the bars) generated by antiSMASH 5.0. Clusters 18, 17, and 11 were described as rishirilides, xiamycins, and mycemycins BGCs, respectively. The putative lobophorin BGC with red color was referred to as cluster 37.](marinedrugs-17-00593-g001){#marinedrugs-17-00593-f001}

![HPLC-based analyses of fermentation broths: (i) *S. olivaceus* SCSIO T05; (ii) *S. olivaceus* SCSIO T05R; (iii) *S. olivaceus* SCSIO T05RX; and (iv) *S. olivaceus* SCSIO T05RXL. Compound **1** is lobophorin CR4. Compounds **2**--**6** were previously identified as rishirilide B, rishirilide C, lupinacidin A, galvaquinone B, and xiamycin A, respectively.](marinedrugs-17-00593-g002){#marinedrugs-17-00593-f002}

![Structure of the isolated lobophorin CR4.](marinedrugs-17-00593-g003){#marinedrugs-17-00593-f003}

![Genetic organizations: (**A**) the *lbp* BGC from *S. olivaceus* SCSIO T05; (**B**) the *lob* BGC from *S.* sp. SCSIO 01127.](marinedrugs-17-00593-g004){#marinedrugs-17-00593-f004}

![Proposed biosynthetic pathway of lobophorin CR4.](marinedrugs-17-00593-g005){#marinedrugs-17-00593-f005}

marinedrugs-17-00593-t001_Table 1

###### 

Genome features of *S. olivaceus* SCSIO T05.

  Feature                                   Value
  ----------------------------------------- -----------
  Genome size (bp)                          8,458,055
  Average GC content (%)                    72.51
  Protein-coding genes                      7700
  Total size of Protein-coding genes (bp)   7,543,173
  rRNAs number                              18
  tRNAs number                              65

marinedrugs-17-00593-t002_Table 2

###### 

AntiSMASH-predicted BGCs for *S. olivaceus* SCSIO T05.

  BGC          Position   Type (Product)   
  ------------ ---------- ---------------- -----------------------------------------------------------------------------------------------------------------------------------------
  Cluster 1    2725       89768            Type I Polyketide synthase (T1 PKS)
  Cluster 2    234616     284137           Non-ribosomal peptide synthetase (NRPS) cluster
  Cluster 3    504553     512728           Bacteriocin or other unspecified ribosomally synthesized and post-translationally modified peptide product (RiPP) cluster (Bacteriocin)
  Cluster 4    525945     544617           Terpene
  Cluster 5    793277     855894           NRPS
  Cluster 6    901333     979368           T1 PKS
  Cluster 7    980891     1005613          Lanthipeptide cluster (Lanthipeptide)
  Cluster 8    1135886    1240760          Other types of PKS cluster (Otherks)-NRPS
  Cluster 9    1275164    1347740          NRPS-Terpene
  Cluster 10   1651711    1694648          NRPS-Nucleoside cluster (Nucleoside)
  Cluster 11   1695020    1734380          Otherks
  Cluster 12   1751698    1796277          NRPS
  Cluster 13   1840051    1851963          Siderophore cluster (Siderophore)
  Cluster 14   1967451    1990613          Lanthipeptide
  Cluster 15   2037772    2059400          Terpene
  Cluster 16   2090680    2102023          Bacteriocin
  Cluster 17   2138860    2187226          T1PKS-NRPS
  Cluster 18   2230691    2317060          NRPS-Type II PKS (T2 PKS)-Otherks
  Cluster 19   2330735    2352337          Lanthipeptide
  Cluster 20   2443907    2456009          Siderophore
  Cluster 21   2905748    2978302          T2 PKS
  Cluster 22   3029068    3048760          Terpene
  Cluster 23   3049806    3075321          Beta-lactone containing protease inhibitor (Betalactone)
  Cluster 24   3182776    3235915          NRPS
  Cluster 25   3764472    3822515          NRPS
  Cluster 26   4131410    4159582          Lanthipeptide
  Cluster 27   4881296    4901736          Phenazine cluster (Phenazine)
  Cluster 28   5633979    5656500          Lasso peptide cluster (Lassopeptide)
  Cluster 29   5716930    5727556          Melanin cluster (Melanin)
  Cluster 30   6667385    6677783          Ectoine cluster (Ectoine)
  Cluster 31   7200930    7253804          NRPS
  Cluster 32   7328818    7368924          Type III PKS (T3 PKS)
  Cluster 33   7614814    7636052          Aminoglycoside/aminocyclitol cluster (Amglyccycl)
  Cluster 34   7882883    7906528          Terpene
  Cluster 35   7959695    7980831          Indole cluster (Indole)
  Cluster 36   8200560    8221618          Terpene
  Cluster 37   8239655    8455702          T1pks-Nrps-T3 PKS-Oligosaccharide cluster (Oligosaccharide)-Other

marinedrugs-17-00593-t003_Table 3

###### 

Deduced function of open reading frames (ORFs) in the *lbp* BGC.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ORF         Size ^a^   Proposed Function                                                      ID/SI ^b^   Protein Homologue and Origin
  ----------- ---------- ---------------------------------------------------------------------- ----------- ------------------------------------------------------------
  *orf(-2)*   374        macrolide glycosyltransferase                                          100/100     Orf(-2) (AGI99472.1); *Streptomyces* sp. SCSIO 01127

  *orf(-1)*   260        FkbM family methyltransferase                                          100/100     Orf(-1) (AGI99473.1); *Streptomyces* sp. SCSIO 01127

  *lbpR1*     195        TetR type regulatory protein                                           100/100     lobR1 (AGI99474.1); *Streptomyces* sp. SCSIO 01127

  *lbpT1*     497        efflux permease                                                        100/100     lobT1 (AGI99475.1); *Streptomyces* sp. SCSIO 01127

  *lbpP1*     392        p450 monooxygenase                                                     100/100     lobP1 (AGI99476.1); *Streptomyces* sp. SCSIO 01127

  *lbpU1*     326        aldo/keto reductase                                                    100/100     lobU1 (AGI99477.1); *Streptomyces* sp. SCSIO 01127

  *lbpS1*     271        sugar-O-methyltransferase                                              99/100      lobS1 (AGI99478.1); *Streptomyces* sp. SCSIO 01127

  *lbpS2*     384        sugar 4-aminotransferase                                               100/100     lobS2 (AGI99479.1); *Streptomyces* sp. SCSIO 01127

  *lbpS3*     201        SAM-dependent methyltransferase                                        97/98       lobS3 (AGI99480.1); *Streptomyces* sp. SCSIO 01127

  *lbpU2*     197        hypothetical protein                                                   100/100     hypothetical protein (KMB22099.1); Klebsiella pneumoniae

  *lbpG1*     391        glycosyltransferase                                                    100/100     lobG1 (AGI99481.1); *Streptomyces* sp. SCSIO 01127

  *lbpA1*     3936       PKS\                                                                   100/100     lobA1 (AGI99482.1); *Streptomyces* sp. SCSIO 01127
                         (KS-AT-DH-ER-KR-ACP-KS-AT-DH-KR-ACP)                                               

  *lbpS4*     483        sugar 2,3-dehydratase                                                  100/100     lobS4 (AGI99483.1); *Streptomyces* sp. SCSIO 01127

  *lbpB*      253        thioesterase                                                           100/100     lobB (AGI99484.1); *Streptomyces* sp. SCSIO 01127

  *lbpP2*     313        FAD-dependent oxidoreductase                                           100/100     part of lobP2 (AGI99485.1); *Streptomyces* sp. SCSIO 01127

  *lbpG2*     416        glycosyltransferase                                                    99/100      lobG2 (AGI99486.1); *Streptomyces* sp. SCSIO 01127

  *lbpG3*     476        glycosyltransferase                                                    99/100      lobG3 (AGI99487.1); *Streptomyces* sp. SCSIO 01127

  *lbpC1*     680        hydrolase superfamily dihydrolipo-amide acyltransferase-like protein   99/99       lobC1 (AGI99489.1); *Streptomyces* sp. SCSIO 01127

  *lbpC2*     75         ACP                                                                    99/100      lobC2 (AGI99490.1); *Streptomyces* sp. SCSIO 01127

  *lbpC3*     621        FkbH-like protein                                                      99/100      lobC3 (AGI99491.1); *Streptomyces* sp. SCSIO 01127

  *lbpC4*     342        ketoacyl acyl carrier protein synthase III                             100/100     lobC4 (AGI99492.1); *Streptomyces* sp. SCSIO 01127

  *lbpP3*     492        FAD-dependent oxidoreductase                                           100/100     lobP3 (AGI99493.1); *Streptomyces* sp. SCSIO 01127

  *lbpA2*     1573       PKS\                                                                   99/100      lobA2 (AGI99494.1); *Streptomyces* sp. SCSIO 01127
                         (KS-AT-KR-ACP)                                                                     

  *lbpA3*     1798       PKS\                                                                   99/99       lobA3 (AGI99495.1); *Streptomyces* sp. SCSIO 01127
                         (KS-AT-DH-KR-ACP)                                                                  

  *lbpA4*     4376       PKS\                                                                   100/100     part of lobA4 (AGI99496.1); *Streptomyces* sp. SCSIO 01127
                         (KR-ACP-KS-AT-DH-KR-ACP-KS-AT-DH-KR-ACP)                                           

  *lbpA5*     2881       PKS\                                                                   99/98       part of lobA4 (AGI99496.1); *Streptomyces* sp. SCSIO 01127
                         (KS-AT-DH-KR-ACP-KS-AT-DH)                                                         

  *lbpA6*     6362       PKS\                                                                   99/99       lobA5 (AGI99497.1); *Streptomyces* sp. SCSIO 01127
                         (KS-AT-ACP-KS-AT-DH-KR-ACP-KS-AT-DH-KR-ACP-KS-AT-DH-KR-ACP)                        

  *lbpU3*     151        unknown                                                                100/100     lobU2 (AGI99498.1); *Streptomyces* sp. SCSIO 01127

  *lbpS5*     414        sugar 3-C-methyl transferase                                           100/100     lobS5 (AGI99499.1); *Streptomyces* sp. SCSIO 01127

  *lbpS6*     373        sugar 3-aminotransferase                                               100/100     lobS6 (AGI99500.1); *Streptomyces* sp. SCSIO 01127

  *lbpS7*     439        acyl-CoA dehydrogenase                                                 100/100     lobS7 (AGI99501.1); *Streptomyces* sp. SCSIO 01127

  *lbpS8*     341        sugar 4,6-dehydratase                                                  100/100     lobS8 (AGI99502.1); *Streptomyces* sp. SCSIO 01127

  *lbpS9*     298        sugar nucleotidyltransferase                                           99/100      lobS9 (AGI99503.1); *Streptomyces* sp. SCSIO 01127

  *lbpS10*    332        sugar 3-ketoreductase                                                  100/100     lobS10 (AGI99504.1); *Streptomyces* sp. SCSIO 01127

  *lbpS11*    202        sugar 5-epimerase                                                      99/100      lobS11 (AGI99505.1); *Streptomyces* sp. SCSIO 01127

  *lbpR2*     274        TetR type regulatory protein                                           99/100      lobR3 (AGI99506.1); *Streptomyces* sp. SCSIO 01127

  *lbpT2*     211        forkhead-associated protein                                            99/100      lobT2 (AGI99507.1); *Streptomyces* sp. SCSIO 01127

  *lbpR3*     298        putative regulatory protein                                            99/100      lobR4 (AGI99508.1); *Streptomyces* sp. SCSIO 01127

  *lbpR4*     309        LysR family transcriptional regulator                                  99/100      lobR5 (AGI99509.1); *Streptomyces* sp. SCSIO 01127

  *orf1*      183        acetyltransferase                                                      100/100     Orf1 (AGI99510.1); *Streptomyces* sp. SCSIO 01127
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Amino acids. ^b^ Identity/similarity.
